Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03803475 · ClinicalTrials.gov registry record · Phase 3
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
A Phase 3 study, sponsored by Thomas Hope.
- Completed
- Registry status
- Phase 3
- Development phase
- 485
- Enrollment target
NCT03803475 is a Phase 3 study that has completed, run by Thomas Hope. The registered enrollment target is 485 participants.
The verdict
NCT03803475, a Phase 3 study, has completed, sponsored by Thomas Hope.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 485 participants
- Enrollment target
Study Summary
The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.
Interventions
- DRUG Ga-68 labeled PSMA-11
- DEVICE Positron emission tomography-computed tomography (PET/CT)
- DEVICE Positron emission tomography-magnetic resonance imaging (PET/MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03803475
The ClinicalTrials.gov registry entry for NCT03803475 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 485 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ga-68 labeled PSMA-11 is the first listed.
NCT03803475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03803475 about?
NCT03803475 is a clinical study titled "Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients". The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.
What is the current status of trial NCT03803475?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 485 participants. The study started on 2018-10-11. Estimated completion is 2020-08-25.
What interventions are being tested in trial NCT03803475?
The interventions under investigation include: Ga-68 labeled PSMA-11 (DRUG), Positron emission tomography-computed tomography (PET/CT) (DEVICE), Positron emission tomography-magnetic resonance imaging (PET/MRI) (DEVICE).
Who is sponsoring clinical trial NCT03803475?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.